[1]刘 星,霍占江.甲状腺乳头状癌组织中galecti-3 与miR-375 水平表达意义及相关性研究[J].现代检验医学杂志,2023,38(01):49-52+185.[doi:10.3969/j.issn.1671-7414.2023.01.010]
　LIU Xing,HUO Zhan-jiang.Expression Significance and Correlation of galectin-3 and miR-375 in Papillary Thyroid Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2023,38(01):49-52+185.[doi:10.3969/j.issn.1671-7414.2023.01.010]
点击复制

甲状腺乳头状癌组织中galecti-3 与miR-375 水平表达意义及相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年01期
页码:
49-52+185
栏目:
论著
出版日期:
2023-01-15

文章信息/Info

Title:
Expression Significance and Correlation of galectin-3 and miR-375 in Papillary Thyroid Carcinoma Tissue
文章编号:
1671-7414（2023）01-049-05
作者:
刘 星; 霍占江
（张家口市第一医院普通外科，河北张家口 075000）
Author(s):
LIU Xing; HUO Zhan-jiang
（Department of General Surgery, the First Hospital of Zhangjiakou City, Hebei Zhangjiakou 075000, China）
关键词:
甲状腺乳头状癌; 半乳糖凝集素3; 微小核糖核酸-375
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.01.010
文献标志码:
A
摘要:
目的 探索甲状腺乳头状癌组织中半乳糖凝集素（galectin）-3 与微小RNA（micro RNA，miRNA）-375 水平表达意义及相关性。方法 选取2014 年5 月～ 2018 年9 月于张家口市第一医院普通外科接受手术治疗的87 例甲状腺乳头状癌患者作为研究对象，收集其甲状腺癌组织及对应的癌旁组织标本。通过实时荧光定量反应（real timepolymerase chain reaction，RT-PCR）检测galectin-3 和miR-375 在各个组织中的表达情况，分析二者的表达关系及其与临床病理特征的相关性。此外，采用酶联免疫吸附（ELISA）法检测入院时患者血清galectin-3 水平，采用RT-PCR 法检测血清miR-375 水平，通过Kaplan-Meier 生存曲线评估血清galectin-3 与miR-375 表达对甲状腺乳头状癌病人预后的影响。结果 与癌旁组织相比，galectin-3 在甲状腺乳头状癌中表达上调（1.77 ± 0.48 vs 0.57 ± 0.16），差异有统计学意义（t=22.122，P ＜ 0.001）；而miR-375 在癌组织中的表达水平下调（1.34 ± 0.39 vs 2.12 ± 0.62），差异有统计学意义（t=9.933，P ＜ 0.05）。galectin-3 表达与肿瘤大小、包膜侵犯、血管浸润、淋巴结转移有关（χ2=9.936~20.028，均P ＜ 0.05）；miR-375 表达与肿瘤大小、血管浸润有关（χ2=12.590，6.403，均P ＜ 0.05）。血清galectin-3 与miR-375 表达水平呈负相关（r=-0.487，P<0.001）。血清galectin-3 高表达者三年总体生存期（overall survival，OS）低于低表达者（71.7％ vs 93.3％），差异有统计学意义（Log-rank=7.493，P=0.001）；miR-375 高表达患者的三年OS 高于低表达者（93.3％ vs 73.9％），差异有统计学意义（Log-rank=7.021，P=0.001）。结论 galectin-3 在甲状腺乳头状癌组织中表达升高，miR-375 在甲状腺乳头状癌组织中表达降低，二者共同参与甲状腺乳头状癌的发生发展，对预后具有一定影响。
Abstract:
Objective To explore the expression significance and correlation of galectin-3 and micro RNA (miR)-375 levels in papillary thyroid carcinoma tissue. Methods 87 patients treated in Department of General Surgery, the First Hospital of Zhangjiakou City from May 2014 to September 2018 were selected as research subjects, and their thyroid cancer tissue and corresponding adjacent cancer tissue specimens were collected. Real-time PCR was performed to investigate the the expression levels of galectin-3 and miR-375 in 87 pairs samples of papillary thyroid carcinoma, and the relationship between galectin-3 and miR-375 expression was analyzed and their relevance to clinicopathologic characteristics of patients with papillary thyroid carcinoma was assessed. Furthermore, serum galectin-3 levels at admission were measured by the enzyme-linked immunosorbent method, and the serum miR-375 levels were measured by RT-PCR. Kaplan-Meier curves were plotted to evlaute the impact of serum galectin-3 and miR-375 expression on the prognosis of papillary thyroid carcinoma patients. Results Compared with adjacent normal tissues, the expression level of galectin-3 was elevated in thyroid cancer tissues (1.77 ± 0.48 vs 0.57 ± 0.16）, the difference was statistically significant（t=22.122, P ＜ 0.001), but the expression level of miR-375 was reduced (1.34 ± 0.39 vs 2.12 ± 0.62), and the difference was statistically significant (t=9.933, P<0.05). Galectin-3 expression was associated with tumor size, capsule invasion, vascular invasion, and lymph node metastasis(χ2=9.936 ～ 20.028，all P ＜ 0.05). The miR-375 expression was related with tumor size and vascular invasion(χ2=12.590, 6.403，all P ＜ 0.05).There was a significant negative correlation between galectin-3 and miR-375 expression in thyroid carcinoma tissues (r=-0.487,P<0.001).Three-year overall survival (overall survival, OS) was lower in the high serum galectin-3 expression than in the low expression patients (71.7% vs 93.3%) , and the difference was statistically significant (Log-rank=7.493, P=0.001), and the 3-year OS of patients with high miR-375 expression was higher than low expression (93.3% vs 73.9%), and the difference was statistically significant (Log-rank=7.021, P=0.001). Conclusion Galectin-3 and miR-375 expression were significantly dysregulated in papillary thyroid carcinoma tissues, and they might be useful biomarkers for the clinical diagnosis and prognostic assessment of papillary thyroid carcinoma.

参考文献/References:

[1] ZUO Xiaoming, SUN Haiwen, FANG Hong, et al.MiR-4443 targets TRIM14 to suppress metastasis and energy metabolism of papillary thyroid carcinoma(PTC) in vitro[J]. Cell Biology International, 2021,45(9): 1917-1925.
[2] NANGIA-MAKKER P, HOGAN V, RAZ A. Galectin-3 and cancer stemness[J]. Glycobiology, 2018, 28(4):172-181.
[3] CYMBALUK-P?OSKA A, GARGULI?SKA P,KWIATKOWSKI S, et al. Could galectin 3 be a good prognostic factor in endometrial cancer[J]. Diagnostics(Basel, Switzerland), 2020, 10(9): 635.
[4] SHANG Peizhong, NAN Runling, WANG Jin, et al.Expression of sialyl lewis X and galectin-3 in papillary thyroid carcinoma and their relationships with invasion and metastasis[J]. Asian Case Reports in Oncology,2017, 6(4): 33-39.
[5] 王永斌, 邓智勇, 肖世闻, 等. 分化型甲状腺癌术后抑制状态下血清甲状腺球蛋白水平检测的临床诊断价值[J]. 现代检验医学杂志, 2019, 34(5): 133-134, 138.
WANG Yongbin, DENG Zhiyong, XIAO Shiwen, et al.Clinical value of serumnon-stimulated thyroglobulin（nS-TG） in differentiated thyroid cancer（DTC） patients in after thyroidectomy [J]. Journal of Modern Laboratory Medicine, 2019, 34(5):133-134,138.
[6] SEMPERE L F, AZMI A S, MOORE A. MicroRNAbased diagnostic and therapeutic applications in cancer medicine[J]. Wiley Interdisciplinary Reviews. RNA,2021, 12(6): e1662.
[7] WANG Xinzheng, HANG Yakai, LIU Jinbiao, et al.Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2[J]. Journal of Pharmacological Sciences, 2016, 130(2): 78-84.
[8] PRASAD P A, RAJU K. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid[J]. Journal of Cancer Research and Therapeutics, 2022, 18(3): 644-649.
[9] 陆伟辉, 王聪, 李宸, 等.Galectin-3 促进甲状腺乳头状癌细胞转移机制的研究[J]. 中国癌症杂志, 2017,27(10): 775-781.
LU Weihui , WANG Cong, LI Chen, et al. The role of Galectin-3 in promoting metastasis of papillary thyroid carcinoma [J]. China Oncology,2017,27(10):775-781.
[10] ZHENG Jiaojiao, LU Weihui, WANG Cong, et al.Galectin-3 induced by hypoxia promotes cell migration in thyroid cancer cells[J]. Oncotarget, 2017, 8(60):101475-101488.
[11] NIE F R, LI Q X, WEI H F, et al. MiR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and ERBB4[J]. Neoplasma, 2020, 67(3): 604-613.
[12] ZOU Xuan, GAO Feng, WANG Zhiyan, et al. A threemicroRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis[J]. Chinese Medical Journal, 2020, 133(21): 2543-2551.
[13] 杨永德, 周焱琳. 浸润性乳腺癌组织中miRNA-206表达与临床病理及预后的关系[J]. 现代检验医学杂志, 2019, 34(4): 45-48.
YANG Yongde, ZHOU Yanlin. Relationship between expression of miRNA-206 and clinical pathology and prognosis in invasive breast cancer [J]. Journal of Modern Laboratory Medicine, 2019, 34(4):45-48.
[14] YANG S I, CHOI Y S. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600EMutation and clinicopathological features[J]. Kosin Medical Journa, 2020, 35(1): 1-14.
[15] 李桂荣, 赵清侠, 宋斌, 等．miR-221 与miR-222 在甲状腺乳头状癌组织中的表达及临床意义[J]. 现代检验医学杂志, 2017, 32(1):41-44.
LI Guirong, ZHAO Qingxia, SONG Bin, et al.Expression of miR-221 and miR-222 in papillary thyroid carcinoma tissues and its clinical significance[J]. Journal of Modern Laboratory Medicine, 2017,32(1):41-44.
[16] 李建华, 徐鹏飞, 邓真, 等. 微小RNA-375 在甲状腺乳头状癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2020, 37(2): 309-312.
LI Jianhua, XU Pengfei, DENG Zhen, et al. Expression of miR-375 in thyroid papillary carcinoma and its clinical significance[J].Chinese Journal of Experimental Surgery, 2020, 37(2):309-312.

相似文献/References:

[1]李桂荣,赵清侠a,宋 斌b,等.miR-221与miR-222在甲状腺乳头状癌组织中的表达及临床意义[J].现代检验医学杂志,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
　LI Gui-rong,ZHAO Qing-xiaa,SONG Binb,et al.Expression of miR-221 and miR-222 in Papillary Thyroid Carcinoma Tissues and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
[2]孟凡萍,郝 坡,范 慧.甲状腺乳头状癌并发桥本氏甲状腺炎患者BRAF-V600E 基因表达及T 淋巴细胞亚群分析[J].现代检验医学杂志,2020,35(01):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
　MENG Fan-ping,HAO Po,FAN Hui.Expression of BRAF-V600E Gene and Analysis of Lymphocyte Subgroup in Thyroid Papillary Carcinoma Combined with Hashimoto's Thyroiditis[J].Journal of Modern Laboratory Medicine,2020,35(01):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
[3]王　玲,王　健,赵寅生,等.甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J].现代检验医学杂志,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
　WANG Ling,WANG Jian,ZHAO Yin-sheng,et al.Clinical Application Value of Serum Thyrotropin Level and Tissue Thyrotropin Receptor Detection in Patients with Thyroid Papillary Carcinoma[J].Journal of Modern Laboratory Medicine,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
[4]宋晓龙,宋 宇,魏 龙,等.血清TK1，TSH，TG，TGAb 检测联合TI RADS 分类在甲状腺乳头状癌早期筛查中的应用价值[J].现代检验医学杂志,2022,37(04):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
　SONG Xiao-long,SONG Yu,WEI Long,et al.Clinical Value of Serum TK1, TSH, TG and TGAb Detection Combined with TI-RADS Classification in Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(01):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
[5]王 勇,张克波.老年心力衰竭患者血清NF-κB，Gal-3 和sST2 水平联合检测与预后评估价值[J].现代检验医学杂志,2022,37(05):148.[doi:10.3969/j.issn.1671-7414.2022.05.029]
　WANG Yong,ZHANG Ke-bo.Prognostic Value of Combined Serum NF-κB, Gal-3 and sST2 Levels in Elderly Patients with Heart Failure[J].Journal of Modern Laboratory Medicine,2022,37(01):148.[doi:10.3969/j.issn.1671-7414.2022.05.029]
[6]宋晓龙,魏 龙,秦晋铝,等.甲状腺乳头状癌患者术前血清TK1 表达水平联合甲状腺超声特征构建中央区淋巴结转移预测模型及验证[J].现代检验医学杂志,2023,38(01):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
　SONG Xiao-long,WEI Long,QIN Jin-lü,et al.Construction and Validation of Prediction Model of Central Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma Based on Preoperative Serum TK1 Expression Level and Thyroid Ultrasound Features[J].Journal of Modern Laboratory Medicine,2023,38(01):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
[7]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[8]薛思军a,涂霁韬b.甲状腺乳头状癌组织中miR-137 水平表达及相关实验研究[J].现代检验医学杂志,2023,38(04):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
　XUE Sijuna,TU Jitaob.Expression of miR-137 in Papillary Thyroid Carcinoma Tissue and Its Related Experimental Study[J].Journal of Modern Laboratory Medicine,2023,38(01):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
[9]周 钧a,汪庭军b,唐 珍a.甲状腺乳头状癌患者血清EGR1/2 mRNA 水平检测在临床早期实验诊断中的价值研究[J].现代检验医学杂志,2023,38(05):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]
　ZHOU Juna,WANG Tingjunb,TANG Zhena.Value of Serum EGR1/2 mRNA Detection in Early Clinical Diagnosis of Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(01):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]

备注/Memo

备注/Memo:
基金项目：张家口市重点研发计划项目（项目编号：1921086D）。
作者简介：刘星（1980-），男，本科，副主任医师，研究方向：普通外科学，E-mail：pking673@163.com。
更新日期/Last Update: 2023-01-15